Skip to Main Content

Paper Details

Reconsideration of Alzheimer's Disease Therapy from a Viewpoint of Amyloidogenic Evolvability.
J Alzheimers Dis Rep
1
2022
AD, Alzheimer's Disease, Alzheimer's disease, activin, adiponectin, amyloidosis, cognitive dysfunction
Author NameAffiliation
Eliezer MasliahNational Institute on Aging
Eliezer MasliahNational Institute on Aging
  • 1 - 2

Datasets

Release 1.2